224 related articles for article (PubMed ID: 12966450)
1. [Cost-effectiveness analysis of enoxaparin for the prophylaxis of venous thromboembolism in major orthopedic surgery patients].
Brosa Riestra M; Rubio-Terrés C; Nadipelli V; Casado Collado A; Martínez Brotons F
Farm Hosp; 2003; 27(4):210-8. PubMed ID: 12966450
[TBL] [Abstract][Full Text] [Related]
2. A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.
Lynd LD; Goeree R; Crowther MA; O'Brien BJ
Can J Clin Pharmacol; 2007; 14(2):e215-26. PubMed ID: 17652767
[TBL] [Abstract][Full Text] [Related]
3. Selecting an agent for prophylaxis of venous thromboembolism.
Myers J
Am J Health Syst Pharm; 2006 Dec; 63(24):2448-50. PubMed ID: 17158692
[No Abstract] [Full Text] [Related]
4. Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients.
McGarry LJ; Thompson D; Weinstein MC; Goldhaber SZ
Am J Manag Care; 2004 Sep; 10(9):632-42. PubMed ID: 15515996
[TBL] [Abstract][Full Text] [Related]
5. Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery.
Honorato J; Gómez-Outes A; Navarro-Quilis A; Martínez-González J; Rocha E; Planès A
Pharmacoeconomics; 2004; 22(13):885-94. PubMed ID: 15329033
[TBL] [Abstract][Full Text] [Related]
6. Cost comparison of tinzaparin versus enoxaparin as deep venous thrombosis prophylaxis in spinal cord injury: preliminary data.
Wade WE; Spruill WJ
Blood Coagul Fibrinolysis; 2001 Dec; 12(8):619-25. PubMed ID: 11734661
[TBL] [Abstract][Full Text] [Related]
7. Economic analysis of low-dose heparin vs the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism after colorectal surgery.
Etchells E; McLeod RS; Geerts W; Barton P; Detsky AS
Arch Intern Med; 1999 Jun; 159(11):1221-8. PubMed ID: 10371230
[TBL] [Abstract][Full Text] [Related]
8. Dabigatran: new drug. Continue to use heparin, a better-known option.
Prescrire Int; 2009 Jun; 18(101):97-9. PubMed ID: 19637411
[TBL] [Abstract][Full Text] [Related]
9. A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.
Lynd LD; Goeree R; Crowther MA; O'Brien BJ
Can J Clin Pharmacol; 2007; 14(2):e215-26. PubMed ID: 18000316
[TBL] [Abstract][Full Text] [Related]
10. Enoxaparin: a pharmacoeconomic review of its use in the prevention and treatment of venous thromboembolism and in acute coronary syndromes.
Bergqvist D
Pharmacoeconomics; 2002; 20(4):225-43. PubMed ID: 11950380
[TBL] [Abstract][Full Text] [Related]
11. A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgery.
Sullivan SD; Davidson BL; Kahn SR; Muntz JE; Oster G; Raskob G
Pharmacoeconomics; 2004; 22(9):605-20. PubMed ID: 15209529
[TBL] [Abstract][Full Text] [Related]
12. Cost consequence analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery in Belgium.
Annemans L; Minjoulat-Rey MC; De Knock M; Vranckx K; Czarka M; Gabriel S; Haentjens P
Acta Clin Belg; 2004; 59(6):346-57. PubMed ID: 15819379
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of low-molecular-weight heparin compared with aspirin for prophylaxis against venous thromboembolism after total joint arthroplasty.
Schousboe JT; Brown GA
J Bone Joint Surg Am; 2013 Jul; 95(14):1256-64. PubMed ID: 23864173
[TBL] [Abstract][Full Text] [Related]
14. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Haentjens P; De Groote K; Annemans L
Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients.
Offord R; Lloyd AC; Anderson P; Bearne A
Pharm World Sci; 2004 Aug; 26(4):214-20. PubMed ID: 15446778
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery.
Gordois A; Posnett J; Borris L; Bossuyt P; Jönsson B; Levy E; de Pouvourville G
J Thromb Haemost; 2003 Oct; 1(10):2167-74. PubMed ID: 14521600
[TBL] [Abstract][Full Text] [Related]
17. Cost analysis: fondaparinux versus preoperative and postoperative enoxaparin as venous thromboembolic event prophylaxis in elective hip arthroplasty.
Wade WE; Spruill WJ; Leslie RB
Am J Orthop (Belle Mead NJ); 2003 Apr; 32(4):201-5. PubMed ID: 12723772
[TBL] [Abstract][Full Text] [Related]
18. Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease.
Cheer SM; Dunn CJ; Foster R
Drugs; 2004; 64(13):1479-502. PubMed ID: 15212562
[TBL] [Abstract][Full Text] [Related]
19. Cost for inpatient care of venous thrombosis: a trial of enoxaparin vs standard heparin.
de Lissovoy G; Yusen RD; Spiro TE; Krupski WC; Champion AH; Sorensen SV
Arch Intern Med; 2000 Nov; 160(20):3160-5. PubMed ID: 11074747
[TBL] [Abstract][Full Text] [Related]
20. Pharmacoeconomics of thrombosis management.
Hawkins D
Pharmacotherapy; 2004 Jul; 24(7 Pt 2):95S-99S. PubMed ID: 15317405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
